Eruptive Sebaceous Hyperplasia: A Rare Consequence of Systemic Corticosteroids

January 2018 | Volume 17 | Issue 1 | Case Reports | 118 | Copyright © January 2018


Geraldine Cheyana Ranasinghe BS and Adam J. Friedman MD

George Washington University School of Medicine and Health Sciences, Washington, D.C.

DISCLOSURES

The authors have no conflicts of interest to declare.

REFERENCES

  1. Gittler J, Penn L, Terushkin V, Brinster N. Diffuse sebaceous-gland hyperplasia. Dermatol Online J. 2016;22(12).
  2. Cortés B, Kaya G. Multiple Eruptive Sebaceous Hyperplasia Secondary to Cyclosporine in a Patient with Bone Marrow Transplantation. Dermatopathology. 2016;3(4):79-82.
  3. Levandoski KA, Girardi NA, Loss MJ. Eruptive sebaceous hyperplasia as a side effect of oral tacrolimus in a renal transplant recipient. Dermatol Online J. 2016;23(5).
  4. Engel F, et al. Diffuse sebaceous hyperplasia of the face induced by cyclosporine. Ann Dermatol Venerol. 2005;132:342.
  5. Burton CS & Sawchuk WS. Premature sebaceous gland hyperplasia: successful treatment with isotretinoin. J Am Acad Dermatol. 1984;12:182.
  6. He Y, Yi W, Suino-Powell K, et al. Structures and mechanism for the design of highly potent glucocorticoids. Cell Res. 2014;24(6):713-726.
  7. Burton CS, Sawchuk WS. Premature sebaceous gland hyperplasia: successful treatment with isotretinoin. J Am Acad Dermatol. 1985;12(1 Pt 2):182-4.

AUTHOR CORRESPONDENCE

Adam Friedman MD ajfriedman@mfa.gwu.edu
Close Menu